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INTRODUCTION 
Preterm labour is an important complication of pregnancy and it is the most 
common cause of neonatal mortality and morbidity. Preterm labour is defined as 
the presence of regular effective uterine contractions of sufficient frequency and 
intensity leading to progressive effacement and dilatation of cervix after the 
period of viability and prior to 37 completed weeks of gestation. Preterm labour 
is a global issue irrespective of region or the level of resources1. 
The global annual incidence of preterm birth in 2005 reported by WHO was 
9.6% of all live births. Developing countries like Africa and Southern Asia 
contribute the highest burden. Preterm birth is a significant cause of perinatal 
mortality and morbidity.Complications include acute respiratory,gastro 
intestinal ,immunologic, centralnervous system, hearing and vision problems as 
well as long term motor,cognitive,visual,hearing,behavioural and growth 
problems. According to WHO, in 2010, 40% of all under 5 deaths occurred in the 
first month of life with prematurity contributing to one third of these deaths. 12% 
of child mortality under 5 years are due to complications of prematurity. Nearly 
one half of all cases of congenital neurologic disability including CP are a 
consequence of prematurity2. India has greatest number of preterm births which 
is about 3.5 million every year3. The incidence of PNMR in India varies from 40 
to 150 per 1000 births in contrast to 10-20 in the developed countries. 
The pathogenesis is not clear whether preterm labour represents early idiopathic 
activation of normal labour process or results from a pathologic mechanism. 
Several theories exist regarding the initiation of labor 1)Progesterone 
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withdrawal ,2)Oxytocin initiation ,3)Premature decidual activation,4)Ascending 
infection. Regardless of the stimulus the final pathway seems to converge 
towards a central role of inflammatory mediators – cytokines. Infection is an 
important cause for preterm labour. Infection produces an intra amniotic 
inflammatory response involving the activation of number of cytokines and 
chemokines which triggers preterm labour. Intrauterine bleeding is another 
important trigger for preterm labour Whatever the mechanism to initiate labour, 
three physiological processes have to occur namely softening and dilatation of 
cervix,uterine myometrial contractions and weekening and rupture of 
membranes. 
Tocolysis (a term proposed by Mosler and Schwalm in Germany) means 
pharmacological inhibition of preterm labour. Improvement of pregnancy 
outcome and neonatal conditions are dependent on gestational age which can be 
obtained by prolongation of pregnancy and corticosteroids4. Over the past few 
years variety of tocolytic drugs with different pharmacologic actions have been 
used to suppress preterm labour. These are beta agonists,calcium channel 
blockers,protaglandin synthetase inbibitors, nitric oxide donors,magnesium 
sulphate and oxytocin receptor antagonists5. The tocolytics basically aims in 
prolonging the pregnancy at least 48 hrs and so provide adequate time to 
administer a course of corticosteroids which would help in preventing RDS in 
newborn and to transfer the women to higher medical centre where adequate 
NICU facilities can be provided to the neonate as and when required. The 
American College Of Obstetrics and Gynecology concluded that despite a 
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number of proposed treatment methods , the rate of preterm labour continues till 
now. 
AIM OF THE STUDY 
1. To compare the effectiveness of transdermal nitroglycerine, intravenous 
MgSO4 and oral nifedipine in prevention of preterm labour 
2. To find the mean prolongation of gestation from the time of admission in 
followed up cases. 
3. To compare the side effects between transdermal nitrogylcerine , intravenous 
MgSO4 and oral nifedipine 
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REVIEW OF LITERATURE 
The definition of prematurity has remained a controversial and debatable issue 
ever since one of the earliest incidences of preterm birth 
In 1907 Simpson referred to a birth on december 25th,1642 when a widow 
delivered a preterm boy who was “so small that he could have been put into a 
quart mug”. The infant grew up to be Sir Isaac Newton 
In 1950, WHO defined prematurity as birthweight 2.5 kg or less. It was derived 
from an idea by a Finish paediatrician who trained in Berlin. He showed babies 
weighing 2.5 kg or less did worse than babies weighing more 
In 1961, WHO revised the definition of prematurity to a gestational age of less 
than 37weeks. 
In 1969,WHO revised the definition so that < 2.5 kg was termed low birth weight 
And <37 weeks was termed preterm. 
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HISTORY OF TOCOLYSIS 
Tocolytics are drugs used to prevent or inhibit preterm labour. The overall goal 
of tocolytic therapy is to improve neonatal outcome. The 3 ways to achieve it by 
tocolytic therapy are 
1) To delay delivery to transfer a women to tertiary care centre where neonatal 
survival and outcome is improved 
2) To prolong pregnancy for atleast 48 hours to complete antenatal 
corticosteroids for fetal lung maturity 
3) To prolong pregnancy as neonatal outcome is directly related to gestational 
age vat delivery. 
The most recent meta analysis demonstrated that antenatal corticosteroids 
decreased the incidence of respiratory distress syndrome, intraventricular 
hemorrhage ,improved neonatal survival and decrease in the incidence of 
necrotising enterocolitis 
First attempt at tocolysis was done by Abramson and Reid in 1955 using Relaxin 
Three main factors contributed to development of tocolysis 
1) Interest in perinatal mortality after Second world war which was 
either due to advances in maternal mortality or whether it was felt 
population of Europe need to be replenished 
2) The discrepencies between birth weight and gestational age 
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3) Emergence of tocography which objectively measures uterine 
contractibility 
In 1961,first publication with beta agonist Isoxsuprine was done by 
Bishop and Wautersz 
Ethanol was introduced as a tocolytic in 1967 by Fuchs but it had unacceptable 
maternal and fetal side effects. Hence dint gain clinical popularity 
Magnesium sulphate was introduced in 1965 by Dumont. The use of magnesium 
sulphate as tocolytic was first described by Steer and Petrie in a randomised 
study of 77 women with preterm labor in 1977. 
Kawagoe et al showed that after magnesium sulphate infusion,90% patients 
prolonged their pregnancy for >48 hrs6. Shamsi Abasalizadeh et al in their study 
concluded that Magnesium sulphate caused delayed delivery of more than 24 
and 48 hours in 32% and 60% of patients7 
In 1979, first prospective double blind trial of Ritodrine was conducted and is the 
only FDA approved drug in 1980 
Nifedipine was introduced in 1977. First study with nifedipine was conducted by 
Ulmsten et al in 1980 which showed similar efficiency with Ritodrine. Calcium 
channel blockers are effective tocolytic agents in preterm labour with 
comparatively lesser side effects than betamimetics8. Sy et al in 2010, concluded 
that nifedipine was an effective, economical and safe drug for tocolysis and that 
it might be used as a substitute for beta agonists in countries with limited 
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resources9 
First observational study of effect of transdermal nitroglycerine patch was done 
by Lees et al in 1994 and it was claimed that this drug was both effective and safe 
in preventing preterm birth. 
Guo et al performed a clinical trial on 153 pregnant women in Canada to assess 
the cost effectiveness of transdermal GTN versus a placebo. They showed that 
the application of transdermal GTN in the context of preterm labour could lessen 
NICU costs and significantly improve neonatal outcome10 
Shaikh et al performed a non randomised clinical trial involving 65 pregnant 
women conducted in pakistan, reported that transdermal GTN was an effective 
and safe tocolytic medication capable of prolonging the pregnancy and 
improving neonatal outcome11. 
In a systematic review and meta analysis published in 2013, it was stated that 
compared with beta 2 adrenergic receptor agonists, transdermal GTN was 
assocaited with a significant decrease in risk of preterm birth, NICU admission 
and maternal adverse effects. Nonetheless,there was no significant differences 
between transdermal GTN and magnesium sulphate and nifedipine in pregnancy 
prolongation and delivery within 48 hours of treatment respectively12 
Despite these trials showing evidence of the probable efficacy of transdermal 
GTN in controlling preterm labour, the most recent update of the Cochrane 
Review included randomized controlled trials involving a total of 1227 patients 
and declared that there was still insufficient evidence to support the routine 
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administration of nitric oxide donors in treatment of preterm labour13 
American college of Obstetrics and Gynecology stated in 2003 guidelines “ no 
optimal first line agent for tocolysis has been identified. Both the potential 
benefits and harms of tocolytic agents need to be considered. Research is needed 
to develop a drug which has a greater uterospecificity with no effect on other 
organs with rapid onset and shorter duration of action”. 
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PRETERM LABOUR 
Preterm labour is defined by WHO as onset of labour prior to the completion of 
37 weeks of gestation beyond 20 weeks of gestation 
The lower limit of this definition is less clearly defined.In India, UK,Singapore 
lower limit is 28 weeks.In USA, lower limit is 20 weeks.FIGO – defines it as 22 
weeks above which fetus is thought to be viable. 
The American academy of Pediatrics and American College of Obstetrics and 
Gynecology (1997) had earlier proposed the following criteria to document 
preterm labour 
1) Uterine contractions of four in 20 minutes or eight in 60 minutes 
plus progressive changes in cervix 
2) Cervical dilatation greater than 1 cm 
3) Cervical effacement of 80% or more 
However currently such clinical findings are now considered inaccurate 
predictors of preterm delivery (ACOG 2003). Thus such explicit criteria do not 
appear in more recent guidelines (ACOG 2008). In addition to painful or 
painless uterine contractions pelvic pressure, menstrual like cramps,watery 
vaginal discharge and low back pain have been empirically associated with 
preterm labour14. 
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Preterm delivery can be spontaneous or induced. Induced preterm births 
contribute 30%. Induction is indicated in various medical or surgical 
complications in mother or fetus that create an unfavourable intrauterine 
environment for the fetus or dangerous environment for the mother. These 
conditions include severe pre eclampsia, chronic hypertension ,diabetes, 
abruptio placenta, IUGR, oligohydramnios etc., 
 
ETIOLOGY OF PRETERM LABOUR 
1.EPIDEMIOLOGY 
• Poor socioeconomic status 
• Low pre pregnancy weight(,40kg) 
• Maternal age( <18 or more than 40) 
• Maternal race black 
• Maternal smoking 
• Strenuous work 
• Short stature 
• Vitamin C deficiency 
• Prev low birth weight 
• Pyschological stress 
• Severe anemia 
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• Prev preterm birth 
• Threatened abortion 
• Prev abortion 
2.CHORIOAMNIONITIS 
Contributes 20-30% of all preterm births.The host responds to infection with 
production of intermediate substances such as interleukin 1, tumor necrosis 
factor, platelet activating factor that activate prostaglandin production by 
decidua and amniotic membranes. May be associated with fever, leucocytosis, 
uterine tenderness, fetal tachycardia. 
3.BACTERIAL VAGINOSIS 
Is a condition in which normal hydrogen peroxide producing lactobacilli 
predominant vaginal flora is replaced with anerobes, gardanella 
vaginalis,mobiluncus ,mycoplasma hominis. 
4.INFECTIONS OUTSIDE UTERUS 
Contributes 5-10% of preterm labour.UTI is the most common 
5. MATERNAL MEDICAL DISORDERS 
Pulmonary or systemic hypertension, renal disease,heart disease, severe anemia, 
malnutrition,obesity, diarhea and dehydration, uncontrolled diabetes leads to 
placental insufficiency trigering hypoxia and stimulating prostaglandin release. 
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6. PLACENTAL ABNORMALITIES 
Placenta previa, abruptio placenta,circumvallate placenta, battledore 
placenta 
7. ANOMALIES OF UTERUS 
1 to 3% of all preterm cases 
80%  bicornuate bicollis uterus 
27%  bicornuate unicollis uterus 
4% septate uterus 
8.CERVICAL INCOMPETENCE 
Rare cause of preterm labour but cervical dysfunction may be involved in 17% 
of preterm labor.with cervical length < 10th percentile (2.5cms at 24 and 28 
weeks), risk of preterm birth increases by 50%. 
9. FETAL PATHOLOGY 
Congenital anomalies like neural tube defects, inborn errors of metabolism like 
potters syndrome, CAH ,hyperprolactinemia 
10. UTERINE OVERDISTENSION 
Multiple pregnancy, hydramnios 
11. PREMATURE RUPTURE OF MEMBRANES 
Amnion after amniotomy is the major site of prostaglandin production 
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12.STRESS 
increased ACTH          Fetal adrenals secrete cortisol          increased 
production of oestrogen         preterm labour 
13. IDIOPATHIC 
20 to 30 % of cases 
ENDOCRINOLOGY OF PRETERM LABOUR 
1)ESTROGEN AND PROGESTERONE 
Estrogen to progesterone ratio is increased producing estrogenic effect.  It 
facilitates prostaglandin production,formation of oxytocin receptors, formation 
of gap junctions which are the early events in preterm delivery 
2)PROSTAGLANDINS 
Estrogenic effect, interleukins, and TNF are the regulators of prostaglandin 
production. Prostaglandins stimulate myometrial contraction 
3)OXYTOCIN 
Oxytocin receptor levels and concentration of oxytocin are increased in women 
destined to develop preterm labour 
4)CORTICOTROPIN RELEASING HORMONE 
Women who go into preterm labour have high level of CRH. It crosses the 
placenta and increases in fetal circulation. Stimulates fetal pituitary and adrenals 
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to produce androgen precursors which increase placental production of 
oestrogens.CRH directly stimulates the myometrium also as CRH receptors are 
found in the myometrium 
5)CYTOKINES 
Increased production of cytokines like IL1,IL2,IL6,IL8 and TNF alpha, 
granulocyte macrophage colony stimuating factor are associated with 
intrauterine infection15. These cytokines stimualte amnion to produce 
prostaglandins which in turn stimulate uterine contractions 
6)SALIVARY ESTRIOL 
90% of the precursors for the production of estriol in maternal circulation comes 
from fetal precursors. Fetal adrenal produces dehydroepiandrostenedione 
sulphate which gets hydoxylated in fetal liver with the help of enzyme 16 
hydroxylase. This gets converted to estriol in placenta. Thus increased stress in 
fetus causes increased fetal adrenal activity and more estriol in maternal 
circulation 
7)RELAXIN 
Is a protein hormone produced by corpus luteum. Increased in first trimester and 
then decreased slightly thereafter but remains elevated in second and third 
trimesters above    normal luteal phase levels. Relaxin is mainly involved in 
cervical ripening. 
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DIAGNOSIS 
Identification of women at risk for preterm labour 
1. Risk scoring system 
2. Warning symptoms of preterm labour 
3. Uterine activity monitoring 
4. Cervical assessment – manual / sonographic assessment 
5. Fetal breathing movements 
6. Biochemical markers 
7. Screening for bacterial vaginosis 
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1.RISK SCORING SYSTEM   
Several factors associated with preterm labour were organized into high risk  
scoring system by Papiernik. This was slightly modified by Gonik and Creasy.   
Poin
ts 
Socioeconomic 
factors 
Previous 
medical 
history 
Daily habits Aspects of 
current 
pregnancy 
1 • Two 
children 
at home 
• Low 
socioeco
nomic 
status 
• Abortion 
*1 
• LCB 
<1year 
Works outside Unusual fatigue 
2  
• Maternal 
age<20 
or >40 
yrs 
• Single 
parent 
 
Abortion
*2 
 
• Smokes 
>10 
cigarett
es per 
day 
• >3 
flights 
of stairs  
Gain of less than 
5kg by 32 weeks 
3 • Very 
low 
socioeco
nomic 
status 
• Height 
<150cm
s 
• Weight 
<45kg 
Abortion
*3 
• Heavy 
work 
• Long 
travel 
• Breech at 
32weeks 
• Weight loss  
• Head 
engaged at 
32 weeks 
• Febrile 
illness 
4 • Maternal 
age 
<18yrs 
 
pyelonephritis  • Bleeding 
after 12 
weeks 
• Short 
cervix 
• Opened 
internal os 
• Uterine 
irritability 
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5  • Uterine 
anomaly 
• Second 
trimester 
abortion 
• DES 
exposure 
• Cone 
biopsy 
 • Placenta 
praevia 
• Hydramnio
s 
•  
10  • Preterm 
delivery 
• Repeated 
second 
trimester 
abortions 
 • Twins  
• Abdominal 
surgery 
 
 
A patient with a score of 10 or more is classified as being at high risk for  
preterm labour.   
Most scoring systems rely on past obstetric history and so are inappropriate for  
nulliparae who constitute more than 40% of all preterm labour patients.   
But Klerman and co workers (2001) found that this failed to identify most  
women who deliver preterm neonates. So it is controversial whether to use this 
or not.   
2. WARNING SYMPTOMS OF PRETERM LABOUR   
• Menstrual like cramps (Constant or come and go, just above the pubic 
bone)  
• Low, dull back ache (Constant or comes and goes)  
• Pressure (Feels like the baby is pushing down, feels heavy).   
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• Abdominal cramping (with or without diarrhoea).   
• Increase or change in vaginal discharge (may be mucosy, watery, light or  
bloody).   
3. UTERINE ACTIVITY MONITORING   
 A sudden increase in uterine activity precedes clinical diagnosis of 
preterm  
labour by 12-48 hrs or even weeks.Ambulatory home uterine activity monitoring 
(HUAM) provides the recording and transmission of uterine activity and consists 
of a patient unit and practitioner unit. The patient unit consists of light weight 
external pressure device, a transmission device and a recorder which can store 
the uterine activity data up to 3  hours. Transmission occurs through a telephone 
to the obstetrician’s unit. Contractions with duration of 35 seconds or longer and 
with an amplitude of greater than 5 mms are considered significant. Until 30th 
week one contraction per hour in primigravida and 2 contractions per hour in 
multigravida are accepted as normal. More than 3 contractions between 26-28 
weeks and more than 5 contractions between 30-32 weeks are considered to be 
predictive of preterm labour and an indication for therapeutic intervention.   
Draw back – These are typically guard ring type surface transducer systems  
that do not measure directly the intensity of uterine contraction which is an 
important  
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consideration in generation of preterm labour.This has been shown to have high 
sensitivity for preterm labour (57-86%) but not for preterm delivery. ACOG 
(1995) concluded that the use of expensive, bulky, time consuming  
system does not reduce the rate of preterm birth  
4. CERVICAL ASSESSMENT   
Wood et al postulated that a short cervix was predictive of preterm 
delivery.   
Sonography of the cervix is a better predictor in women at risk of preterm birth 
than by digital examination. Transvaginal ultrasound is better than 
transabdominal ultrasound because the proximity of optical focal length allows 
close inspection of cervical canal and it removes bladder as a confounding 
variable.  Dilated internal os greater than 1 cms at or before 30 weeks – 20% 
risk of preterm labour.  
Cervical length < 25 cms at 24-28 weeks gestation or the presence of a funnel  
that accounts for 50% of cervical length predicts an increased risk for preterm  
delivery.   
If < 25% of cervical length is replaced by funnel, preterm delivery rate is 17%.  
If greater than 50% of length is replaced by funnel, the rate of preterm delivery  
increases to 79%. Presence of funnel at 24 weeks is associated with preterm 
delivery. 
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with a sensitivity of 25.4%, specificity of 94.5% positive predictive value of 
17.3% and negative predictive value of 96.6%41.   
         Cervical index = Funnel length +  1 /  Endocervical length. A cervical 
index of 0.52 was associated with a sensitivity of 76% and specificity of 94% for 
prediction of preterm labour.   
Cervical score = Cervical length (cms) – Cervical dilatation (cms)42. 
Score of ‘0’ or below is associated with positive predictive value of 66-75% for 
predicting preterm labour. Currently there is no strong evidence to support 
routine cervical assessment as a screening tool for population at low risk but it 
can be used in high risk population.   
5. FETAL BREATHING MOVEMENTS   
 Absence of fetal breathing movements within 48 hours predicts preterm 
labour with a sensitivity of 66.7% and is due to suppression of breathing 
movement by  elevated PGF2α in the amniotic fluid  
6. BIOCHEMICAL MARKERS 
• Cervico vaginal fetal fibronectin   
• Mediators of inflammation: interleukin, phospholipase A2, glycolipid 
ceramide lactoside, tumor necrosis factor.   
• Markers of maternal and fetal stress: CRH, serum, salivary and urinary 
estriol.   
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Other markers which have been studied are tissue inhibitor of metallo 
proteinase, relaxin, plasma progesterone, progesterone: oestrogen ratio, 
alfafetoprotein, 
Fetal fibronectin   
 It is a glycoprotein, produced by the chorion and is localized to the decidua  
basalis. It acts as a glue that attaches fetal membranes to the underlying decidua. 
Its presence in cervicovaginal secretion indicates disruption of chorio-decidual 
junction by labour or by inflammation44. Presence of fetal fibronectin > 50ng/ml 
between 21and 35 weeks gestation is a good predictor of preterm with a 
sensitivity of 52%, specificity of 93%, PPV-46%, NPV of 94%45. Absence of 
fetal fibronectin is a strong predictor that preterm delivery is unlikely within next 
7-14 days and so unnecessary interventions can be avoided. The predictive 
power of fibronectin is stronger at earlier gestational ages (24-28 weeks) than in 
later pregnancy.   
False positive results are obtained in the following situations:  
Bleeding (moderate or heavy)   
Ruptured membranes   
Intercourse within past 24 hours.   
Digital cervical examination within past 24 hours.   
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False negative results:  
 Lubricant (e.g. surgilude or K-Y jelly)   
 Soaps or disinfectants (Betadine, Hexachlorophene).   
Screening of women at high risk with fibronectin has been recommended.   
Salivary estriol   
 Diurnal secretion pattern is present with a flat nadir during day light hours  
(9.00 am to 6.00 pm) and a peak in the early morning hours.   
 Level > 2.1 ng/dl has a sensitivity of 40% specificity of 93%, PPV of 19% and  
NPV of 97% in detecting preterm labour.  
 Administration of maternal glucocorticoids for fetal lung maturation in  
preterm labour decreases salivary estriol level to 23% of pretreatment levels for  
approximately 1 week.   
7. SCREENING FOR BACTERIAL VAGINOSIS   
 Bacterial vaginosis is a condition in which normal hydrogen peroxide  
producing lactobacillus predominant vaginal flora is replaced with anaerobes, 
Gardnerella vaginalis, Mobilinus species and Mycoplasma hominis.  Women 
with this infection whose vaginal secretions contained sialidase have 
significantly increased risk of preterm labour.  But screening and treatment of 
this have not been shown to prevent preterm birth.   
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MANAGEMENT OF PRETERM LABOUR 
Management of preterm labour depends on the presentation of patient at the 
time the problem was identified. 
I – Patients at high risk for preterm labour 
II – Patients who develop warning signs of preterm labour. 
III – Patients in established preterm labour. 
MANAGEMENT OF PATIENTS AT HIGH RISK FOR PRETERM 
LABOUR 
I. Prepregnancy counseling 
• Evaluation of nutritional status and screening for anaemia 
• Child bearing at right age. 
• Adequate spacing between pregnancies. 
• Avoidance of multiple MTP’s 
• Assess for Chlamydia and bacterial vaginosis and any positive result should 
be treated. 
• UTI should be investigated and treated. 
• Refrain from cigarette smoking. 
II. Education about preterm labour 
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Patient should be given education about the subtle nature of early symptoms 
and signs of excessive uterine activity. 
III.  Aggressive treatment of cervical and vaginal infections 
Treating infections may be the most important preventive measure in patients 
at risk for preterm labour. Patients at risk for preterm labour should have a 
speculum examination one and vaginal or cervical infection with Gardnerella 
vaginalis or Chlamydia trachomatis or Group B streptococcus should be treated 
immediately. 
IV. Serial ultrasound examination 
Patients at high risk should be monitored with ultrasound examinations every 
4 weeks starting at 16 weeks. The purpose of these examinations is to evaluate 
cervical length and also to detect signs of placental insufficiency. 
V. Coital abstinence 
Discontinuation of coital activity is mandatory if patient has noticed strong 
contractions after coitus or at the time of orgasm. 
VI. Behavioural alteration 
Avoid strenuous activities,Avoid exercise ,To rest in left lateral position  
,Modification of working conditions. 
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MANAGEMENT OF PATIENTS WITH WARNING SIGNS OF 
PRETERM 
LABOUR 
I. Bed rest - Bed rest in lateral position usually decreases the frequency and 
intensity of uterine contractions. It also increases birth weight by increasing 
placental perfusion. 
II. Behavioural alteration 
III. Treatment of infections like bacterial vaginosis, urinary tract infections. 
IV. Prophylactic tocolysis -Tocolysis is indicated in patients with warning signs 
of preterm labour because stopping uterine contractions may prevent further 
cervical effacement and the loss of mucous plug. Despite lack of support from 
academic community, theprophylactic use has been generalised throughout the 
world. Commonly used drugsinclude β sympathomimetics, calcium channel 
blockers, magnesium sulphate 
V. Cervical encirclage to prevent preterm labour 
It has been tried to prevent preterm delivery in patients with ultrasonographic 
evidence of short cervix. But there is currently insufficient evidence to warrant 
theplacement of cervical encirclage in a patient solely on the basis of shortened 
cervical length. 
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MANAGEMENT OF PATIENTS WITH ESTABLISHED PRETERM 
LABOUR 
In this group confusion in treatment arises whether prolongation of pregnancy 
should be attempted or not. Choice must be made among three management 
options – 
1) To arrest labour and prolong pregnancy until term or as close to term as 
possible. 
2) To arrest labour for atleast 48-72 hrs to allow time for therapeutic effects of 
corticosteroids. 
3)To let labour continue. 
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CONTRAINDICATIONS TO INHIBIT PRETERM LABOUR : 
MATERNAL FACTORS FETAL FACTORS 
• Maternal diseases like 
preeclampsia, uncontrolled 
diabetes, chronic renal disease, 
severe cardiac 
disease,SLE,hyperthyroidism, 
sickle cell anemia 
• Advanced labour ( >5cm cervical 
dilatation and 100% effacement) 
• Maternal hemorhage 
• Chorioamnionitis 
• Fetal death 
• Congenital anomalies 
• IUGR 
• Fetal distress 
 
 
TOCOLYSIS 
AIM 
• To stop delivery till the completion of antenatal steroids 
• To transfer baby in utero to higher centre 
  
28 
 
IDEAL TOCOLYTIC 
• Should inhibit uterine activity 
• Should not alter maternal or fetal hemodynamics 
• Should not cause side effects to mother and fetus 
• Should not alter course of labour 
• Should not cause 3rd stage complications 
AVAILABLE TOCOLYTICS 
1) Beta adrenergic receptor agonist 
a) Non selective – isoxsuprine hydrochlroide, orciprenaline 
b) Selective beta 2 agonist- ritodrine,terbutaline,salbutamol 
2) Calcium channel blockers 
3) Magnesium sulphate 
4) Nitric oxide donors 
5) Prostaglandin synthetase inhibitors 
6) Oxytocin antagonist – atosiban 
7) Ethanol 
8) Potassium channel openers 
9) Miscellaneous – progesterone ,diazoxide 
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NITRIC OXIDE DONORS 
Nitric oxide is an important modulator of contractile function in a variety of 
smooth muscle cells. In pregnancy, there is upregulation of nitric oxide, 
probably through the action of oestrogen. Nitric oxide also has been implicated 
in peripheral vasodilatation in pregnancy and in the control of blood flow in 
fetoplacentalcirculation. More recently it has been hypothesized that nitric oxide 
plays a role inmaintenance of uterine quiescence during pregnancy. 
Nitroglycerine 
Nitroglycerine was first synthesized in 1846 by Sobrero. In 1879, William 
Murrell decided that action of Nitroglycerine mimicked that of amylnitrate and 
sublingual Nitroglycerine was used for relief of anginal attack. Nitroglycerine is 
a potent smooth muscle relaxant and was used for removal of intrapartum 
version of 2nd twins. Lees and associates (1994) used Nitroglycerine patches in 
13 women in preterm labour and claimed that this drug was both effective and 
safe in preventing preterm birth. 
 
  
30 
 
MECHANISM OF ACTION 
It is rapidly de nitrated in smooth muscle to release reactive free radical 
 nitric oxide 
 
Guanyl cyclase is activated 
 
Increased cyclic GMP 
 
Dephosphorylation of myosin light chain kinase 
 
Myosin fails to interact with actin 
 
Relaxation 
Increased cyclic GMP also decreases calcium entry and causes 
relaxation.Also decreases CRH and causes relaxation 
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DOSAGE 
10mg transdermal nitogycerine patch is applied to the skin of abdomen. If after 
one hour, no reduction in contraction strength and frequency ,another 10 mg 
patch is applied. Maximum dose is 20mg /24 hours 
CONTRA INDICATIONS 
• Hypersensitivity to nitrate compounds 
• Hypotension 
• Increased ICT 
• Myocardial insufficiency 
• Glaucoma 
• HOCM 
SIDE EFFECTS 
• Throbbing headache 
• Hypotension,tachycardia 
• Nausea,flushing, dizziness 
• Methhemoglobinemia 
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CALCIUM CHANNEL BLOCKERS 
The degree of activation of smooth muscle contractile proteins is directly related 
to changes in cytoplasmic calcium concentration. The concentration of free 
calcium in the cytoplasm can be increased by entry of calcium through either 
voltage dependant or receptor operated channels. An increase in free calcium 
results in calcium binding to calmodulin, which subsequently phosphorylates 
and activates myosin light chain kinase, resulting in activation of myosin and 
contraction. 
MECHANISM OF ACTION 
Calcium channel blockers bind to L type voltage dependant calciuस channels 
reducing their permeability to calcium ions. They also cause a decrease in 
calcium release from intracellular stores.Nifedipine, Nicardipine, Verapamil are 
the potent calcium channel blockers.The 1,4 di hydro pyridine type blockers i.e. 
Nifedipine and Nicardipine are more selective inhibitors of uterine contractions. 
Nifedipine is the most commonly used drug. 
DOASGE 
30 mg orally followed by 20 mg after 90 minutes and maintenance dose of 
10-20 mg 8th hourly. 
Different loading dose regimens are - 
1) 10 mg sublingual every 20 minutes for up to three doses. 
2) 10 mg sublingual with 20 mg oral 
3) 30 mg oral. 
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CONTRAINDICATIONS 
• Maternal hypotension 
SIDE EFFECTS 
• Flushing ,headache,dizziness,nausea 
• Transient hypotension 
ADVANTAGES 
• Does not affect carbohydrate metabolism , can be given in diabetic 
mothers 
• Does not alter cardiac rhythm . 
• Excellent drug in chronic hypertension 
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BETAMIMETICS 
Beta 1 receptors are present in heart , small intestine and adipose tissue 
Beta 2 receptors are present in smooth muscles, bronchiloes,diaphragm, uterus 
 
 
 
 
 
 
 
Stimulation of beta receptors also increases hepatic glycogen production and 
insulin production in pancreas 
Ritodrine 
Ritodrine is rapid acting. Serum levels reach 75% of maximum in 20 
Minutes 
 
 
  
Increase in cyclic GMP 
 Decrease in free 
calcium                                             
  Beta 2 agonists in uterus 
Dephosphorylates myosin light 
chain kinase 
   Inhibits muscle contarction 
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Intravenous treatment 
Continuous intravenous infusion. Start infusion at a rate of 100 μg/min. Increase 
every 10 minutes by 50 μg/min, until contractions stop, pulse rate exceeds 120 
b/min, toxicity appears or a maximal rate of 350 μg/min. Once adequate dose is 
reached it should be maintained for 12 hours after contractions stop 
 
Oral Treatment 
Give 10 mg tablet orally and 30 minutes later discontinue the I.V. infusion. 10 
mg every 2 hours should be given for next 24 hours. Then adjust dose to 10-20 
mg 
every 4-6 hours as necessary. 
Terbutaline 
Most commonly used dosing regimen is 250 μg subcutaneously every 20 
minutes to 3 hours, stopping the dose for pulse rate greater than 120 b/min.  
Onset of action is rapid, within 3-5 minutes after subcutaneous administration. 
Isoxsuprine    Intravenous infusion: Start at a rate of 0.2-0.5mg/min increasing 
or reducing it according to the effect on blood pressure and heart rate. 
Intramuscular injection: Duvadilan 10 mg IM every 1-2 hours followed by 
maintenance dose of 60-80 mg daily orally or intramuscularly. 
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CONTRAINDICATIONS 
ABSOLUTE RELATIVE 
Cardiac arrhythmias Sickle cell disease 
Thyrotoxicosis Pre eclampsia 
Daiabetes mellitus Twins 
 Asthamtics 
SIDE EFFECTS 
MATERNAL FETAL 
Arrythmias Tavhycardia 
Pulmonary edema Hyperstimulation 
Myocardial ischemia Hyperglycemia 
Hypotension Myocardial,septal hypertrophy 
Tachycardia NEONATAL 
Hyperglycemia Tachycardia 
Hyperinsulinemia Hypoglycemia 
Altered thyroid functions Hyperbilirubinemia 
Tremors Hypotension 
Palpitaions Intraventricular hemorrhage 
Nausea,vomiting 
Fever 
Hallucinations 
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MAGNESIUM SULPHATE 
MECHANISM OF ACTION 
Competitive antagonism to calcium entry into myocytes with decreased free 
intracellular calcium resulting in decreased myocardial contractality16 
DOSAGE 
4g to 6g bolus over 20 minutes followed by maintenance dose of 1-2 g / 
hour.Urine output, respiratory rate, deep tendon reflexes monitored. Therapeutic 
level 5-8meq/l. 
CONTRAINDICATION 
• Mysthenia gravis 
• Cardiac decompensation 
SIDE EFFECTS 
MATERNAL NEONATAL 
Flushing Lethargy 
Lethargy Respiratory depression 
Headache Demineralisation 
Weakness Hypotonia 
Diplopia 
Dry mouth 
Pulmonary edema 
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PROSTAGLANDIN SYNTHETASE INHIBITORS 
Prostaglandins E and F are mediators of uterine contraction and decrease in their 
production causes decreased uterine contractility. Indomethacin is the 
commonly used. 
DOSAGE 
Loading dose of 100 – 200 mg rectally or 50-100 mg orally , maintenance dose 
25-50mg 4-6th hourly 
CONTRA INDICATIONS 
• Renal / hepatic dysfunction 
• Active peptic ulcer 
• NSAID sensitive asthma 
• Coagulation disorders 
• Thrombocytopenia 
SIDE EFFECTS 
MATERNAL FETAL 
Nausea Premature closure of ductus arteriosus 
Heart burn Decrease in renal function 
 Intraventricular hemorrhage 
 Necrotising enterocolitis 
 Hyperbilirubinemia 
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OXYTOCIN ANTAGONISTs 
Atosiban is a nanopeptide – competitive antagonist of oxytocin17 
DOSAGE 
Intravenous infusion of 300micro gm /min continued until 6 hours after 
cessation of contractions upto maximum of 12 hours 
SIDE EFFECTS 
MATERNAL -Nausea, vomiting,headache 
Does not affect the fetus 
ETHANOL 
First tocolytic used to prevent preterm birth 
MECHANISM OF ACTION 
• Inhibits secretion of oxytocin 
• Reduces myocardial oxytocin receptors 
• Non competitive antagonism at uterine level 
Currently not used because of significant maternal and fetal side effects 
PROGESTERONE 
MECHANISM OF ACTION 
• Antagonistic effect on prostaglandin F2 alpha and to adrenergic 
stimulation 
40 
 
• Block development of gap junctions necessary for propagation of 
muscular activity 
• Decreases concentration of myometrial oxytocin receptors18 
DOSAGE 
Micronised form 50mg every 8-12 hours 
 
DIAZOXIDE 
MECHANISM OF ACTION 
Smooth muscle relaxant 
DOSAGE 
5mg/kg slow i.v over 15 to 30 minutes 
SIDE EFFECTS 
MATERNAL FETAL 
Hypotension Hyperglycemia 
Tachycardia Fetal distress 
Hyperglycemia  
 
ANTENATAL CORTICOSTEROIDS 
In 1972, corticosteroid treatment of pregnant women delivering prematurely 
was first introduced to enhance fetal lung maturity. 
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MECHANISM OF ACTION 
Corticosteroids bind with transport proteins in the maternal circulation. Free and 
bound forms exist and only the free forms enter the fetal cells where it is bound 
to intracellular glucocorticoid receptors. 
Pulmonary effects 
Cause stimulation of differentiation of epithelial cells into type II pneumocytes, 
synthesis and release of surfactant from type II pneumocytes into alveolar spaces 
and acceleration of structural development 
Extra plulmonary effects 
Corticosteroids accelerate cytodifferentiation, protein and enzyme synthesis ina 
variety of tissues including liver, pancreas, kidney, intestines, adrenals, skin 
andmyocardium.  Accelerated maturation of fetal intestines reduces the 
incidence of necrotizing enterocolitis. Catecholamine responsiveness of vessels 
reduces incidence of IVH in extremely preterm infants. 
The two preferred synthetic corticosteroids are: 
Betamethasone & Dexamethasone. These fluorinated compounds are 
stereoisomers or mirror images of one another with identical biologic activity 
that readily cross the placenta in their biologically active forms, devoid of 
mineralocorticoid activity, relatively weak in immunosuppressive activity and 
exert longer duration of action than cortisol and prednisolone with half life of 
36-72 hrs. 
National institute of health consensus panel recommendations for use of 
antenatal corticosteroids 
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1. The benefits of antenatal administration of corticosteroids to fetuses at 
risk for preterm delivery outweigh the potential risks. These benefits 
include not only reduction in the risk for RDS but also substantial 
reduction in mortality and IVH. 
2. All fetuses between 24-34 weeks gestation at risk for preterm delivery 
should be considered candidates for antenatal treatment with 
corticosteroids. 
3. The decision to use antenatal corticosteroids should not be altered by 
fetal race or gender or by the availability of surfactant replacement 
therapy. 
4. Patients eligible for therapy with tocolytics should also be eligible for 
treatment with antenatal corticosteroids. 
5. Treatment consists of 2 doses of 12 mg of Betamethasone administered 
intramuscularly 24 hours apart or 4 doses of 6mg of dexamethasone 
administered intramuscularly 12 hours apart.Optimal benefit begins 24 
hours after initiation of therapy and lasts 7 days. 
6. Because treatment with corticosteroids for less than 24 hours is still 
associated with significant reduction in neonatal mortality, RDS and IVH, 
antenatal corticosteroids should be administered unless immediate 
delivery is anticipated. 
7. In complicated cases in which delivery before 34 weeks is imminent 
antenatalcorticosteroid use is recommended unless there is evidence that 
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corticosteroidswill have adverse effects on the mother and delivery is 
imminent. 
Recent studies have shown that higher or more frequent doses donot 
increase the benefits of antenatal corticosteroid therapy but may increase 
the likelihood of side effects. 
MATERNAL SIDE EFFECTS 
Potential adverse maternal side effects include infection, hyperglycemia, 
pulmonary edema, adrenal suppression. Threat of preterm delivery persists or 
recurs after the initial administration of corticosteroid therapy. 
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METHODOLOGY 
This study was undertaken at GOVERNMENT MOHAN 
KUMARAMANGLAM MEDICAL COLLEGE AND HOSPITAL, Salem. 
Between January 2016 to December 2016. 
SELECTION OF PATIENTS 
120 patients who were admitted and clinically diagnosed as preterm labour were 
selected randomly after inclusion criteria were fulfilled. The selected patients 
were randomised either to group A treated with intravenous magnesium 
sulphate, group B treated with transdermal nitroglycerine patch, group C treated 
with oral nifedipine. All 3 groups were given intramuscular corticosteroids. 
INCLUSION CRITERIA 
1. Gestational age between 28 to 37wks as determined by menstrual 
dates, clinical examination, USG. 
2. Uterine contractions: 2 contractions in 10 minute period, each 
contraction lasting for 40 sec. 
3. Progressive cervical effacement upto 75%. 
4. Cervical dilatation upto 3 cm. 
5. Intact membranes. 
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EXCLUSION CRITERIA 
Maternal Factors 
1. Rupture of Membrane 
2. Infection 
3. Cervical dilatation greater than 3 cm 
4. Antepartum hemorrhage 
5. Pregnancy induced hypertension 
6. Chronic hypertension 
7. Cardiac disease 
8. Previous caesarean section 
9. Renal disease 
10. Pulmonary disorder – Asthmatics, ARDS. 
11. sensitivity or contraindication to nitrogycerine/ mgso4/nifedipine 
12.hypotension 
Fetal Factors 
1. Multiple gestation 
2. Fetal death / distress 
3. IUGR 
4. Congenital anomalies 
5. Polyhydramnios / Oligohydramnios 
6. Erythroblastosis . 
When a case of preterm labour meeting the inclusion criteria was admitted 
detailed history was taken regarding age, occupation, socioeconomic status, and 
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any history of infections, obstetric history, and history of previous preterm 
deliveries, abortions, history of diabetes mellitus, heart disease, chronic renal 
failure, hypertension, and asthma. 
Patient’s general physical examination was done. Vitals were recorded 
.Cardiovascular system and respiratory system examined. 
Period of gestation was calculated from Naegeles rule in patients with known 
last menstrual period, otherwise assessed by clinical examination and 
ultrasound. 
Abdominal examination-uterine heights, presentation, position, lie of the fetus, 
liquor volume, fetal heart rate were recorded.  Uterine contractions were 
evaluated with respect to frequency and duration. 
Per speculum examination -any discharge/leak/bleed from cervix  
noted.Presence or absence of herniation of membranes noted. 
Per vaginal examination – the consistency, position, effacement, dilatation of 
cervix, status of membranes, and station of presenting part noted. 
The following investigations are done 
• Complete blood count 
• Blood grouping & typing 
• Urine routine 
• Urine culture & sensitivity 
• High vaginal swab culture and sensitivity 
Informed written consent obtained from all patients. 
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GROUP A 
The patients were given 4gm of MgSO4 in 20%solution as an intravenous 
loading dose given over a period of 20 minutes. After the loading dose was 
given,intravenous infusion was started at the rate of2gm/hour. The intravenous 
infusion was continued for 12hours after uterine quiescence was achieved. The 
infusion was discontinued if patient developed tachycardia, hypotension, absent 
patellar jerks, signs of respiratory depression, decreased urine output, intolerable 
nausea and vomiting or fetal distress. 
GROUP B 
Transdermal nitroglycerine patch brand name NITRODERM 10mg, was applied 
to a clean, dry area of intact skin on the fundus of the uterus. Uterine contractions 
were reassessed after 2 hours of application of the patch, and if relaxation of 
uterus occured the patch was continued for 24 hours or till full dose of steroid 
administration. In instances where uterine contractions did not subside after 2 
hours of application of the patch, a second patch was applied. With the 
application of the second patch, if uterine contractions subsided it was  
continued for 24 hours. On the second day, this patch was removed and another 
patch was applied for completion of steroid course. Inspite of second patch on 
the first day, if the uterine contractions did not subside then patch was discarded 
and another rescue tocolytic was used. Treatment was discontinued, if there was 
maternal tachycardia greater than 120 beats/minute, drop of blood pressure 15 
mm of Hg or more from baseline diastolic pressure, fever more than 100F or 
premature rupture of membranes. 
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GROUP C 
Patients diagnosed with preterm labour pains were given 10mg oral nifedipine 
stat followed by 10mg every 20mins upto 40mg in first hour. 20mg nifedipine 
every 4 hour was repeated upto 48 hours. Treatment was discontinued if patient 
developed headache, tachycardia, hypotension. 
Monitoring 
1. Half an hourly abdominal palpation to note frequency and strength of 
contractions for 2 hours and then 6th hourly 
2. Pulse, BP, Fetal heart rate monitoring every ½ hourly for 2 hours and then 6th 
hourly. 
3. Close monitoring for any side effects. 
If contractions subside, patients were discharged and assessed antenatally every 
week until delivery. All patients received injection dexamethasone 6mg 1M 12 
hours apart 4 doses. Patients received antibiotics if indicated.   Gestational age 
at delivery, mode of delivery, birth weight, APGAR at 1 minute and 5 minutes 
was recorded in followed up cases. 
Definition of Success 
Treatment is considered successful if uterine contraction subsided and tocolysis 
achieved for > 48 hours. 
Definition of failure 
The therapy was said to have failed when the patient delivered within 48 hours of 
initiation of therapy. 
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Tocolytic was stopped when cervical dilation progressed to > 3 cms or when the 
membranes ruptured spontaneously. Hence this study confines itself to the study 
of idiopathic spontaneous preterm labour, comparing the efficacy of 
nitroglycerine patch, iv MgSO4, oral nifedipine in prolonging pregnancy for 
atleast 48 hours and studying the maternal and fetal effects. 
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RESULTS 
Total number of cases assigned to the study was 120. They were randomly 
divided into 3 groups 
Group A – treated with intravenous magnesium sulphate 
Group B -treated with Transdermal nitroglycerine 
Group C – treated with oral nifedipine 
The collected data were analysed with IBM.SPSS statistics software 23.0 
Version.To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & S.D 
were used for continuous variables. To find the significant in the multivariate 
analysis the one way ANOVA with Tukey's Post-Hoc test was used.To find the 
significance in categorical data Chi-Square test was used. In all the above 
statistical tools the probability value .05 is considered as significant level. 
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Table 1 – Distribution   according to maternal age 
Age in 
years 
 Group A Group B Group C TOTAL 
18 to 20 Count 12 5 15 32 
Percentage 30% 12.5% 37.5% 26.7% 
21 to 25 Count 15 26 15 56 
Percentage 37.5% 65.0% 37.5% 46.7% 
26 to 30 Count 12 9 9 30 
Percentage 30% 22.5% 22.5% 25% 
Above 30 Count 1 0 1 2 
Percentage 2.5% 0% 2.5% 1.7% 
Total Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
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Graph 1 Distribution   according to maternal age 
 
 
This shows that majority of patients in all three groups were between 21 to 25 
years. 
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Table 2 Distribution   according to mean maternal age in groups 
Groups Frequency Mean maternal age in 
years 
Group A 40 23.68 
Group B 40 23.48 
Group C 40 22.68 
Total 120 23.28 
 
 
Graph –2 Distribution   according to mean maternal age in groups 
 
Mean maternal age was 23.68 in group A, 23.48 in group B, 22.68 in group C. 
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Table 3 – Distribution   according to antenatal care 
Antenatal 
care 
 Group A Group B Group C TOTAL 
Booked Count 37 39 38 114 
Percentage 92.5% 97.5% 95% 95% 
Unbooked Count 3 1 2 6 
Percentage 7.5% 2.5% 5.0% 5.0% 
Total Count 40 40 40 120 
percentage 100% 100% 100% 100% 
 
 
Graph 3- Distribution   according to antenatal care
 
Majority of the patients were booked . 92.5% in group A, 97.5% in group B, 95% 
in group C. 
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Table 4. Distribution   according to obstetric score in groups 
Obs score  Group A Group B Group C TOTAL 
Primi Count 16 21 28 65 
Percentage 40% 52.5% 70% 54.2% 
Multi Count 24 19 12 55 
Percentage 60% 47.5% 30% 45.8% 
Total Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
 
 
Graph 4. Distribution   according to obstetric score in groups 
 
Preterm labour is more common in primigravida than multigravida. 54.2 % of 
the study population primi and 45.8 % multi. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group A Group B Group C
Obstetric Score
PRIMI MULTI
56 
 
Table 5 Distribution   of gestational age at presentation between groups 
Gestational 
age 
 Group A Group B Group C TOTAL 
28-30.6 Count 8 2 0 10 
Percentage 20% 5% 0% 8.3% 
31-33.6 Count 9 11 14 34 
Percentage 22.5% 27.5% 35.5% 28.3% 
34-36.6 Count 23 27 26 76 
Percentage 57.5% 67.5% 65.0% 63.3% 
Total Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
 
Graph 5- Distribution   of gestational age at presentation in groups 
 
Majority of cases in all 3 groups were between 34 – 36.6 weeks. 57.5% in group 
A, 67.5% in group B, 65% in group C. 
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Table 6- Distribution   according to mean gestational age at presentation in 
groups 
Groups Frequency Mean gestational age 
Group A 40 32.7 
Group B 40 34.1 
Group C 40 34.1 
 
Mean gestational age at presentation was 32.7 in group A, 34.1 in group B and 
34.1 in group C. 
 
Table 7- Distribution   according to gestational age at delivery 
 
Gestational 
age at delivery 
 Group A Group B Group C TOTAL 
28-30.6 weeks Count 1 0 0 1 
Percentage 2.5% 0% 0% 0.8% 
31-33.6weeks Count 4 2 6 12 
Percentage 10% 5% 15% 10% 
34-36.6weeks Count 28 26 27 81 
Percentage 70% 65% 67.5% 67.5% 
>37 weeks Count 7 12 7 26 
Percentage 17.5% 30% 17.5% 21.7% 
Total 
 
Count 40 40 40 120 
percentage 100% 100% 100% 100% 
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Graph 6- Distribution   according to gestational age at delivery 
Most of the patients delivered above 34 weeks 87.5% in group A, 95% in group 
B, 89.2% in group C. 
 
Table-8 Distribution   according to mean gestational age at delivery in 
groups 
 
Groups Frequency Mean gestational age 
Group A 40 35.29 
Group B 40 36.05 
Group C 40 35.19 
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Table 9 Distribution   according to prolongation of days 
Prolongation in 
days 
 Group A Group B Group C TOTAL 
1 day Count 6 5 6 17 
Percentage 15% 12.5% 15% 14.2% 
2 day Count 2 2 6 10 
Percentage 5% 5% 15% 8.3% 
>2 day Count 32 33 28 93 
Percentage 80% 82.5% 70% 77.5% 
Total Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
 
 
Graph 7 Distribution   according to prolongation of days 
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Table-10 Distribution   according to mean prolongation of pregnancy in days 
Groups Frequency Mean prolongation in 
days 
Group A 40 12.28 
Group B 40 13.5 
Group C 40 7.45 
 
 
Graph –8 Distribution   according to mean prolongation of pregnancy in 
days 
 
Mean prolongation of pregnancy was 12.2 days in group A, 13.5 in group B, 7.45 
in group C 
group A group B group C
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Table- 11 Distribution   according to success rates 
 Group A Group B Group C  
Success Count 33 35 33 101 
Percentage 82.5% 87.5% 82.5% 84.2% 
Failure Count 7 5 7 19 
Percentage 17.5% 12.5% 17.5% 15.8% 
Total Count 40 40 40 120 
percentage 100% 100% 100% 100% 
 
Graph –9 comparison of success and failure rate between the three groups 
 
Success rate was 82.5% in group A, 87.5% in group B, 82.5% in group 
0 5 10 15 20 25 30 35 40
GROU
P A
GROU
P B
GROU
P C
success failure
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table -12 Distribution   of maternal side effects in groups 
Maternal 
side effects 
 Group A Group B Group C TOTAL 
Headache Count 3 8 4 15 
Percentage 7.5% 20% 10% 12.5% 
Palpitation Count 0 6 5 11 
Percentage 0% 15% 12.5% 9.16% 
Hypotension Count 0 3 9 12 
Percentage 0% 7.5% 22.5% 10% 
Hot flushes Count 13 0 0 13 
Percentage 32.5% 0% 0% 10.8% 
Vomiting Count 2 4 5 11 
Percentage 5% 10% 12.5% 9.16% 
None Count 22 19 17 58 
Percentage 55% 47.5% 42.5% 48.33% 
Total Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
 
The most common side effect associated with MgSO4 was hot flushes (32.5%), 
NTG was headache (20%) and nifedipine was hypotension(22.5%) 
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Graph 10 showing Distribution   of maternal side effects 
 
 
 
Table-13 Distribution   according to birth weight in kilograms 
Birth weight in kg Group A Group B Group C TOTAL 
1.5-1.9 
kg 
Count 5 2 7 14 
Percentage 12.5% 5% 17.5% 11.7% 
2-2.49 kg 
 
Count 17 16 21 54 
Percentage 42.5% 40% 52.5% 45% 
>2.5 kg Count 18 22 12 52 
Percentage 45% 55% 30% 43.3% 
 Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
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Graph 11 Distribution   of birth weight in kg 
 
Most of the babies more than 2 kg , 87.5% in group A, 80% in group B, 88.3% in 
group C. 
 
 
Table 14 Distribution   according to mean birth weight in babies 
Groups Frequency Mean birth weight 
Group A 40 2.366 
Group B 40 2.473 
Group C 40 2.297 
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Graph 12 Distribution   according to mean birth weight in babies 
 
Mean birth weight in babies in group A was 2.366 kg, group B was 2.473 kg, 
group C was 2.297 kg. 
 
 
Table-15 Distribution   according to neonatal outcome 
  Group A Group B Group C TOTAL 
 
NICU admission Count 5 2 5 12 
Percentage 12.5% 5% 12.5% 10% 
Mother side Count 35 38 35 108 
Percentage 87.5% 95% 87.5% 90% 
Total Count 40 40 40 120 
Percentage 100% 100% 100% 100% 
 
2.2 2.25 2.3 2.35 2.4 2.45 2.5
group A
group B
group C
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Graph13 Distribution   according to neonatal outcome 
 
Most of the babies about 90% were mother side. 
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DISCUSSION 
Preterm labour remains one of the unconquered frontiers in the present era of 
Obstetrics. Throughout the years a variety of drugs with different pharmacologic 
principles are used to suppress preterm labour. The choice is limited by their 
efficacy,safety and side effects. Despite the availability of tocolytic agents the 
rate of prematurity has not declined over the past few years for several reasons. 
Firstly, the etiology is usually not known. So it is difficult to devise a method that 
will predict which group of patients go into labour and delivery. Second, the 
signs and symptoms of threatened preterm labour are frequently subtle. Thus 
very often patients present themselves for care too late to the obstetricians to 
attempt to inhibit preterm labour and prevent a premature delivery. Third, 
although most cases fall into the category of idiopathic preterm labour certain 
clinical entities like PIH, APH etc, may require immediate termination 
regardless of maturity of fetus. 
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MATERNAL AGE DISTRIBUTION   
Majority of patients in the study were between 21 to 25 years. Mean maternal 
age was 23.28. 
Table 16 Distribution   according to mean maternal age in different studies 
STUDY YEAR MEAN AGE 
LB Lipi21 2013 28 
M Kashanian 22 2014 23.33 
Sandhya Rani and 
Lakshmi23 
2015 21.68 
S Tabassum25 2015 30 
ShanthiRani 
Balasubramani26 
2017 23.9 
Present study  23.28 
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DISTRIBUTION   ACCORDING TO PARITY 
In this study 54.2% of the population was primi. 
Table 17 Distribution   according to parity in different studies 
Study Year Parity 
Singh N20 2011 Multi(53.5%) 
LB Lipi21 2013 Multi (56.5%) 
Sandhya Rani and 
Lakshmi23 
2015 Multi (57%) 
Shanthi Rani 
Balasubramani26 
2017 Primi 50%, multi 50% 
Hangekar P27 2017 Primi (54%) 
Present study  Primi(54.2%) 
Hence this study is comparable with above mentioned studies. 
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MEAN GESTATIONAL AGE AT PRESENTATION 
Most of the patients in this study were between 34- 36.6 weeks. (63.3%). 28.3% 
were between 31-33.6 weeks. 8.3% were between 28-30.6 weeks 
 
Table 18 mean gestational age at presentation in different studies 
STUDY YEAR MEAN GESTATIONAL 
AGE 
M Kashanian 22 2014 31.45 weeks 
Sandhya Rani and 
Lakshmi23 
2015 32.3 weeks 
Ghomian et al24 2015 31.9 weeks 
S Tabassum25 2016 32.5 weeks 
Present study  33.63 weeks 
 
In this study mean gestational age at presentation was 33.63 weeks. 
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SUCCESS RATE WITH INTRAVENOUS MAGNESIUM SULPHATE 
Table 19 comparison of success rate with intravenous magnesium sulphate in 
different studies 
STUDY YEAR PERECNTAGE 
Yasuyuki Kawagoe19 2011 50% 
LB Lipi21 2013 76.09% 
S Tabassum25 2016 88.8% 
Present study  82.5% 
In this study success rate with magnesium sulphate was 82.5% 
SUCCESS RATE WITH TRANSDERMAL NITROGLYCERINE PATCH 
Table 20 comparison of success rate with transdermal nitroglycerine patch in 
different studies 
STUDY YEAR PERCENTAGE 
M Kashanian 22 2014 86.7% 
Sandhya Rani and 
Lakshmi23 
2015 90% 
Shanthi Rani 
Balasubramani 26 
2017 72% 
Present study  87.5% 
 
In this study success rate of nitroglcerine was 87.5%. 
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SUCCESS RATE WITH ORAL NIFEDIPINE 
Table 21 comparison of success rate with oral nifedipine in different studies 
STUDY YEAR PERCENTAGE 
Singh N20 2011 80% 
S Tabassum25 2016 74.4% 
Shanthi Rani 
Balasubramani26 
2017 90% 
Present study  82.5% 
 
In this study success rate with oral nifedipine was 82.5% 
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MATERNAL SIDE EFFECTS 
SIDE EFFECTS WITH INTRAVENOUS MAGNESIUM SULPHATE 
Table 22 comparison of side effects of magnesium sulphate with another study 
 Srividya Nemani28 Present study 
Hot flushes 46% 32.5% 
Vomiting 28% 5% 
Headache 12% 7.5% 
 
In this study most common side effect with MgSO4 was hot flushes. Hence is 
comparable with above study 
SIDE EFFECTS WITH TRANSDERMAL NITROGLYCERINE PATCH 
Table 23 comparison of side effects of NTG patch with another study 
 Sandhya Rani23 Present study 
Headache 10% 20% 
Palpitation 2% 15% 
Hypotension 0% 7.5% 
Vomiting 4% 10% 
Skin rash 6% 0% 
The most common side effect in this study was headache 20% which is 
comparable with the above mentioned study 
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SIDE EFFECTS WITH ORAL NIFEDIPINE 
Table 24 comparison of side effects of oral nifedipine with another study 
 Sandhya Rani23 Present study 
Headache 0% 10% 
Palpitation 8% 12.5% 
Hypotension 14% 22.5% 
Vomiting 0% 12.5% 
 
In this study most common side effect with nifedipine was hypotension which is 
comparable with the above mentioned study 
MEAN BIRTH WEIGHT 
Table 25 comparison of mean birth weight in different studies 
STUDY YEAR BIRTH WEIGHT 
Ghomian et al24 2015 2.1kg 
Shanthi Rani 
Balasubramani26 
2017 2.2 kg 
Hangekar P27 2017 2.2 kg 
Present study  2.3kg 
 
In this study mean birth weight was 2.3kg. 
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SUMMARY 
The study was conducted in Govt Mohan Kumaramanglam Medical College and 
Hospital Salem in the Department of Obstetrics and Gynecology between 
January 2016 to December 2016. 
The study group consisted of 120 patients with preterm labour who were divided 
into 3 groups of 40 each 
Group A- treated with intravenous magnesium sulphate 
Group B-treated with transdermal nitroglycerine 
Group C-treated with oral nifedipine. 
• Majority of patients belonged to the age group 21-25 years.(  MgSO4 
group -37.5%, NTG group - 65% and Nifedipine group -37.5%) 
• Mean age of patients in MgSO4 group -23.68, NTG group -23.48, 
Nifedipine Group -22.68. 
• Majority of the patients were booked and immunized(95%) 
• Majority of the patients in the study were primi (54.2%) 
• Mean gestational age at presentation was 32.7 in MgSO4 group , 34.1 in 
NTG group  and Nifedipine group. 
• Success rate was 87.5% with NTG group , 82.5% with MgSO4 and 
Nifedipine group. 
• Mean prolongation of pregnancy was 12.28 days in MgSO4 group, 13.5 
in NTG group,7.45 in Nifedipine group 
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• Most common side effect with MgSO4 was hot flushes (32.5%), NTG 
was headache(20%) and nifedipine was hypotension (22.5%) 
• Mean birth weight was 2.366kg in MgSO4 group, 2.473kg in NTG group, 
2.297 kg in Nifedipine group. 
• Neonatal outcome was similar in all groups 
• Though the success rates and mean prolongation of pregnancy was not 
statisfically significant between the groups, NTG was found to be more 
effective in prolonging pregnancy for 48 hours compared to MgSO4 and 
nifedipine . 
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CONCLUSION 
Prevention and proper treatment of preterm labour is essential to reduce perinatal 
mortality and morbidity and improve the quality of life. An ideal tocolytic 
should postpone delivery at low cost without maternal and fetal side effects. This 
study concluded that transdermal nitroglycerine patch has higher efficacy 87.5% 
for acute tocolysis of preterm labour as compared to Magnesium sulphate and 
oral nifedipine. The most common side effect was headache which could be 
controlled with analgesics. Nitroglycerine is well tolerated and safe for the 
mother and fetus. Nitroglycerine patch should be used as a first line tocolytic 
agent in cessation of preterm labour so that some benefit could be achieved from 
prolongation of pregnancy by enabling corticosteroid administration to 
accelerate fetal lung maturation and improve outcome for both mother and fetus. 
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ANNEXURE 
PROFORMA 
COMPARITIVE STUDY OF TRANSDERMAL NITROGLYCERINE/ 
INTRAVENOUS MAGNESIUM SULPHATE/ ORAL NIFEDIPINE IN 
PREVENTION OF PRETERM LABOR 
1. S. NO.                          7. Date of Admission 
2. NAME & ADDRESS              8. Date of Delivery 
3. AGE                                9. Date of Discharge 
4. I.P.NO:                             10.  Socio-Economic status 
5. Ward / Unit                        11. Occupation 
6. Booked / Unbooked                12. Education 
13.  HISTORY OF: 
Amenorrhoea of  Months 
Pain abdomen 
Bleeding P/V 
Discharge P/V 
Leaking P/V 
Dysuria/Frequency of micturition 
Headache/blurring of vision/Pedal oedema 
83 
 
14. OBSTETRIC HISTORY: 
Married life Consanguinous/Nonconsanguinous 
Gravida     para      living        Abortions 
Previous Pregnancies- Preterm births/Abortions/Cervical trauma/Spacing 
between 
pregnancies/Mode of delivery 
15. MENSTRUAL HISTORY : 
Age of menarche                Past menstrual cycles 
LMP 
EDD 
Period of gestation 
16. PAST HISTORY: 
H/o DM / HTN / TB / Previous surgeries / bronchial asthma / Epilepsy 
17. FAMILY HISTORY: 
H/o DM / HTN / TB / Twinning / Congenital anomalies / asthma 
18. PERSONAL HISTORY: 
19. GENERAL PHYSICAL EXAMINATION : 
Built   Nourishment 
Pallor   Pedal edema     Pulse   BP   RR 
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Weight                        Height 
Thyroid   Breast   Spine 
20. SYSTEMIC EXAMINATION: 
CVS    RS 
P/A   Fundal height 
Uterine Contractions-Frequency 
Duration 
Presentation 
FHS 
P/S    Active leak 
Discharge 
P/V     Cervical Effacement 
Dilatation 
Consistency 
Position 
Membranes-Present/Absent 
Station of Presenting Part 
21. INVESTIGATIONS : 
Hb%      Blood group  TC   DC 
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HIV  HBSAg     VDRL                         RBS 
Urine- albumin/Sugar/Microscopy 
Urine C/S 
USG 
22. TREATMENT: 
Tocolytic agent used ; Transdermal nitroglycerine patch/  intravenous magnesium 
sulphate/ oral nifedipine 
Time interval between treatment & stoppage of uterine contractions : 
Side effects  :   Headache / Hypotension / Tachycardia /vomiting / skin rash 
Duration of therapy 
Other treatment given :Steroids 
Antibiotics 
23.FOLLOW UP : 
Prolongation of pregnancy-       days 
Labour- Term / Preterm -          weeks 
Birth weight- 
Apgar 1min and 5min- 
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1 AISHWARYA 20 71623 A 4 Booked PRIMI 29.2 3 2 50% 2 29.3 1 1.5 6 A HOT FLUSHES
2 ALAMELU 22 72164 B 3 Booked PRIMI 35.2 3 2 30% 4 36.1 6 2.4 7 M PALPITATION
3 AMUDHA 19 11505 A 4 Booked PRIMI 36 3 2 50% 2 36.1 1 2.1 7 M NONE
4 AMUDHA 25 66411 B 5 Booked PRIMI 35.4 3 2 50% 2 35.5 1 2.4 7 M NONE
5 ANANDHI 23 74314 B 4 Booked G2P1L1 34.2 3 2 30% 4 35.2 7 2.6 7 M HEADACHE
6 ANITHA 22 73022 A 3 Booked G2P1L1 32.6 3 2 30% 4 34.7 15 2.2 7 M NONE
7 ANURADHA 22 64359 B 4 Booked PRIMI 35.4 3 2 50% 2 35.5 1 2.6 7 M HEADACHE
8 ARTHI 27 68792 B 4 Booked G3P1L1A1 34.6 3 2 30% 4 36.2 10 2.7 7 M NONE
9 BANU 22 74235 B 5 Booked PRIMI 33 3 2 30% 4 35.5 19 2.3 7 M NONE
10 BARGATH BANU 22 73371 B 4 Booked PRIMI 36.1 2 2 30% 4 37.2 8 2.2 7 M PALPITATION
11 BHUVANESHWARI 22 75086 A 5 Booked PRIMI 35 3 2 30% 4 35.4 4 2.6 7 M HEADACHE
12 BHUVANESHWARI 20 11420 A 5 Booked PRIMI 28.4 2 2 30% 4 32.4 28 1.9 6 A NONE
13 CHITRA 24 67108 B 4 Booked PRIMI 36.1 3 2 50% 2 36.2 1 2.8 7 M HYPOTENSION
14 CHITRA 23 58592 C 5 Booked PRIMI 32 3 3 50% 4 32.3 3 1.8 7 A VOMITING
15 DEEPA 24 71316 A 4 Booked G2P1L1 3 3 2 30% 4 35.4 3 2.5 7 M HOT FLUSHES
16 DEEPIKA 20 69101 C 3 Booked PRIMI 33.5 3 2 30% 4 37.1 24 2.5 8 M HYPOTENSION
17 DHANALAKSHMI 18 63962 C 4 Booked PRIMI 32 3 2 50% 3 32.3 2 1.8 7 A HEADACHE
18 DHANALAKSHMI 25 72405 A 5 Booked G3P2L2 35.1 3 3 50% 2 35.2 1 2.5 8 M HOT FLUSHES
MASTER CHART
19 DHIVYA 23 71812 B 5 Booked PRIMI 36 2 2 50% 4 36.4 4 2.2 7 M HEADACHE
20 GAYATHRI 24 56694 C 4 Booked PRIMI 34 3 2 30% 4 34.5 5 2.1 7 M HYPOTENSION
21 GAYATHRI 19 58876 C 4 Booked PRIMI 35.2 3 2 30% 4 35.5 3 2.24 8 M NONE
22 GEETHANJALI 26 74108 B 4 Booked PRIMI 35.3 2 2 30% 4 36.4 8 2.4 8 M NONE
23 GOMATHI 26 50904 C 5 Un Booked G3P2L2 35.2 3 2 30% 4 38.4 23 2.6 8 M HYPOTENSION
24 GOVINDHU 36 75091 A 5 Un Booked G4P3L3 35.3 3 2 50% 2 35.4 1 2.7 7 M HOT FLUSHES
25 GOWRI 19 57530 C 4 Booked PRIMI 35.3 3 3 30% 4 35.6 3 2.25 8 M NONE
26 HAJEERA 24 65437 B 3 Booked PRIMI 34.3 3 2 30% 4 36.5 16 2.7 7 M PALPITATION
27 HASEENA 27 11195 A 4 Booked G2P1L1 35.5 3 2 30% 4 37.2 11 3 8 M NONE
28 INDHUMATHI 26 53161 C 4 Booked G2P1L1 34.5 3 3 50% 3 34.6 1 1.9 7 M HEADACHE
29 INDHUMATHI 19 61162 C 5 Booked PRIMI 35.2 3 2 50% 2 35.3 1 2.3 7 M HYPOTENSION
30 JAMUNARANI 25 71733 A 3 Booked G2P1L1 36.3 3 2 50% 3 36.5 2 2.7 7 M NONE
31 JANAKI 20 71505 A 4 Booked G2P1L1 35 3 2 30% 4 35.3 3 2.2 7 M NONE
32 JAYAKODI 30 21082 A 5 Un Booked G4P3L3 32.5 3 2 30% 4 34.2 11 1.9 7 A HOT FLUSHES
33 JEEVA 30 59772 B 5 Booked PRIMI 35.2 3 2 30% 4 35.6 4 2.6 8 M HYPOTENSION
34 JEYANTHI 27 72172 B 5 Booked G2A1 30 3 2 30% 4 34.2 30 2.2 7 M NONE
35 KAJAL 19 75237 B 5 Un Booked PRIMI 32.4 3 2 30% 4 32.6 2 1.9 6 A NONE
36 KAJAL 19 70084 A 5 Un Booked PRIMI 29.5 3 1 50% 4 33.2 25 1.9 6 A VOMITING
37 KALA 27 22213 C 4 Booked PRIMI 33.2 4 2 50% 2 33.3 1 1.95 8 M PALPITATION
38 KALAIARASI 22 24194 A 4 Booked G2P1L1 30.6 3 2 30% 4 34.3 25 2.3 8 M HOT FLUSHES
39 KALAISELVI 23 65661 B 4 Booked G3A2 32 3 2 30% 4 35.3 24 2.1 7 M NONE
40 KALAIVANI 22 61757 C 5 Booked PRIMI 34.3 3 2 30% 4 34.6 3 2.3 7 M HYPOTENSION
41 KALYANI 26 67435 A 4 Booked G3P1L1A1 33.2 3 2 30% 4 36.3 22 2.4 8 M HOT FLUSHES
42 KARPAGAM 20 70639 C 5 Booked PRIMI 35.5 3 2 50% 4 36 2 2.4 8 M NONE
43 KASTHURI 23 59534 B 4 Booked PRIMI 33.5 3 2 50% 2 33.6 1 1.8 6 A NONE
44 KAVITHA 23 67892 A 4 Booked PRIMI 35.1 3 2 50% 4 35.4 3 2.6 7 M HOT FLUSHES
45 KEERTHIKA 21 71867 A 4 Booked PRIMI 33.3 3 2 30% 4 36.2 20 2.3 7 M NONE
46 KOKILA 19 54696 C 5 Booked PRIMI 35.2 3 2 30% 4 36.1 6 2.5 8 M VOMITING
47 KOWSALYA 20 71135 A 4 Booked PRIMI 33.2 3 2 30% 4 34.1 6 2 7 M HEADACHE
48 KOWSALYA 19 21134 A 4 Booked PRIMI 31.4 3 2 30% 4 35.3 29 2.2 7 M NONE
49 LAKSHMI 19 56418 C 4 Booked PRIMI 33.4 3 2 30% 4 34.1 4 2.1 7 M VOMITING
50 MAHALAKSHMI 27 11401 A 4 Booked G2A1 36.2 3 3 50% 2 36.3 1 2.7 7 M NONE
51 MAHESHWARI 22 60495 C 4 Booked PRIMI 35 3 2 30% 4 35.4 4 2.5 8 M HEADACHE
52 MAHESHWARI 22 60495 C 4 Booked PRIMI 35 3 2 30% 4 35.4 4 2.5 8 M NONE
53 MAHESHWARI 23 67158 C 5 Booked PRIMI 33 2 1 30% 4 38.4 39 3 8 M NONE
54 MANJULADEVI 27 71232 A 4 Booked G3P2L2 30.3 3 2 50% 4 34 25 2.2 7 M NONE
55 MEGALA 26 75053 A 5 Booked G2P1L1 32.4 3 2 30% 4 36.3 27 2.25 7 M NONE
56 MUTHUSELVI 22 58779 B 5 Booked G2P1L1 34.5 3 2 50% 4 37.1 17 2.8 8 M HEADACHE
57 MYTHILI 30 60591 C 5 Un Booked G4P3L3 34 3 2 30% 4 34.3 3 2.2 7 M NONE
58 MYTHILI 28 59236 C 5 Booked G3P2L2 34.4 3 2 30% 4 35.2 5 2.25 7 M NONE
59 MYTHILI 24 62912 B 4 Booked G2P1L1 35 3 2 30% 4 38.2 23 3 8 M VOMITING
60 NATHIYA 25 75230 A 3 Booked G2P1L1 34.6 3 2 30% 4 37.2 17 2.8 8 M NONE
61 NIROSHA 28 73241 A 4 Booked G3P2L1 34 3 2 30% 4 37.2 23 2.5 8 M HOT FLUSHES
62 NITHYA 27 72537 B 4 Booked G2P1L1 35 2 2 30% 4 38 21 2.8 8 M NONE
63 NITHYA 19 73786 A 5 Booked PRIMI 35.2 3 2 30% 4 37.1 13 2.6 8 M NONE
64 NITHYA 22 64325 B 4 Booked PRIMI 35 3 2 30% 4 36.4 11 2.5 7 M NONE
65 PARVATHI 25 11352 A 4 Booked PRIMI 35.1 3 2 30% 4 35.4 3 2.1 7 M HOT FLUSHES
66 PAVITHRA 19 55384 C 5 Booked PRIMI 36.2 3 3 50% 2 36.3 1 2.8 8 M HYPOTENSION
67 PAVITHRA 23 53650 C 4 Booked PRIMI 32.3 3 2 30% 4 32.6 3 1.8 7 A NONE
68 PODHAMAL 23 68815 C 5 Booked PRIMI 34.1 3 2 50% 2 34.2 1 2.15 7 M NONE
69 PONGODI 23 61133 C 4 Booked PRIMI 32 3 3 50% 4 32.2 2 1.6 7 A NONE
70 POUNAMMA 21 11335 A 5 Booked G2A1 34.1 3 2 30% 4 35.2 8 2.3 8 M HEADACHE
71 PRIYA 24 66795 B 3 Booked PRIMI 34.2 3 2 30% 4 36.2 14 2.3 7 M HEADACHE
72 PRIYA 20 59461 C 4 Booked PRIMI 36.3 3 2 30% 4 36.6 3 2.45 8 M NONE
73 PRIYA 29 74230 B 5 Booked G2P1L1 33.2 3 2 30% 4 37.4 30 2.6 7 M NONE
74 PRIYA 25 68106 C 4 Booked PRIMI 33.2 3 2 30% 4 33.4 2 2.1 7 M PALPITATION
75 PRIYA 26 75364 B 4 Booked G3P2L2 35 3 2 30% 4 36.5 12 2.1 7 M PALPITATION
76 PRIYA 23 74488 B 4 Booked G2P1L1 35 3 2 30% 4 36.6 13 2.5 8 M VOMITING
77 RAJI 20 11289 A 4 Booked PRIMI 35 3 2 30% 4 37.5 19 2.9 8 M HOT FLUSHES
78 RAMYA 22 74108 B 4 Booked G3P1L1A1 33 2 2 30% 4 37.4 32 2.7 8 M NONE
79 RAMYA 23 73670 B 4 Booked G2P1L1 36 3 2 30% 4 38.4 18 2.8 8 M NONE
80 RANI 20 74417 A 4 Booked G2P1L1 34.6 3 2 30% 4 37.4 19 2.8 8 M NONE
81 RASATHI 19 66263 C 3 Booked PRIMI 34.5 3 2 50% 4 34.7 2 2.2 7 M PALPITATION
82 RASITHA BEGUM 23 66461 C 4 Booked G2P1L1 36 3 2 50% 4 37.2 9 2.9 8 M NONE
83 REVATHY 30 72418 A 5 Booked G2P1L1 35.4 3 3 50% 4 35.6 2 2.6 8 M NONE
84 REVATHY 21 75352 B 4 Booked PRIMI 31.3 3 2 30% 4 34.5 23 2.2 7 M VOMITING
85 ROJA 25 65728 B 5 Booked G2P1L1 35.2 3 2 30% 4 37.1 13 2.8 7 M PALPITATION
86 RUPA 23 63312 B 3 Booked G2P1L1 35.3 3 2 30% 4 37.2 13 2.8 8 M VOMITING
87 SABEENA 21 60068 B 4 Booked PRIMI 33.2 3 2 30% 4 34.1 8 2.1 7 M NONE
88 SAKTHIKEERTHANA 20 70092 A 4 Booked PRIMI 35 3 2 30% 4 36.1 8 2.2 7 M NONE
89 SANGEETHA 23 64264 C 3 Booked G2P1L1 34.2 3 2 30% 4 37.4 24 2.6 7 M NONE
90 SANTHIYA 18 69859 C 4 Booked G3P2L2 34.3 3 2 30% 4 35.2 6 2.5 7 M NONE
91 SARANYA 24 60874 B 4 Booked G2P1L1 35 2 2 50% 2 35.1 1 2.1 7 M HEADACHE
92 SARANYA 25 70063 A 3 Booked G3P2L2 30.3 3 2 30% 4 34.2 27 2.4 7 M HOT FLUSHES
93 SARANYA 20 55924 C 5 Booked PRIMI 35.5 3 3 50% 2 35.6 1 2.1 8 M PALPITATION
94 SARANYA 22 74321 B 5 Booked PRIMI 33.5 3 2 30% 4 35.4 13 2.6 7 M PALPITATION
95 SARASWATHY 18 72305 A 4 Booked PRIMI 32.3 3 2 30% 4 33 4 2 8 M NONE
96 SAREENA 27 64351 C 5 Booked PRIMI 34 3 2 30% 4 37.2 23 2.9 8 M NONE
97 SATHYA 21 11437 A 5 Booked G2P1L1 28.2 3 1 25% 4 34.3 43 2.5 8 M VOMITING
98 SATHYAPRIYA 26 11304 A 4 Booked G3P2L2 32.5 3 3 50% 2 32.6 1 1.8 7 A NONE
99 SATHYARANI 29 21119 A 4 Booked G4P1L1A2 35.2 3 2 50% 4 35.5 3 2.1 7 M NONE
100 SEETHA 22 66543 A 5 Booked G3P2L1 34.4 3 2 30% 4 36.2 12 2.5 7 M NONE
101 SELVALAKSHMI 20 58030 B 4 Booked G3P1L1A1 34 3 2 30% 4 37.2 23 2.7 7 M NONE
102 SELVALAKSHMI 20 58030 C 3 Booked G3P1L1 34.1 3 2 30% 4 34.4 3 2 7 M PALPITATION
103 SELVI 27 56703 C 3 Booked G2P1L1 33 3 2 30% 4 35.3 17 2.1 8 M HYPOTENSION
104 SELVI 19 66325 B 5 Booked PRIMI 35 3 2 30% 4 35.4 4 2.2 8 M NONE
105 SELVI 27 66543 A 4 Booked PRIMI 35.3 3 2 30% 4 37.6 17 2.9 7 M NONE
106 SENBAGAM 22 60167 C 4 Booked G2P1L1 32.5 3 2 30% 4 34.4 13 2.4 7 M HYPOTENSION
107 SENTHAMARAI 24 60556 C 4 Booked G2P1L1 34.2 3 3 50% 4 34.4 2 2.4 7 M VOMITING
108 SHANMUGAPRIYA 21 59584 C 4 Booked PRIMI 32 3 2 30% 4 35.2 16 2 7 M HYPOTENSION
109 SHANTHI 24 64355 B 4 Booked G2P1L1 34.3 3 2 30% 4 36.4 15 2.5 7 M HYPOTENSION
110 SHARMILA 26 57463 C 4 Booked PRIMI 33.5 3 2 50% 4 35 7 2.4 8 M HEADACHE
111 SHENBEGAM 21 66341 B 5 Booked PRIMI 33.2 3 2 30% 4 38.4 37 3.2 8 M NONE
112 SREEJA 28 61710 C 4 Booked PRIMI 34.4 3 2 30% 4 36.2 12 2.4 7 M NONE
113 SUGAVATHI 26 11435 A 3 Booked G3P2L2 34.3 3 2 30% 4 35 4 2.4 7 M HOT FLUSHES
114 VANATHI 29 72410 B 5 Booked G3P2L2 30.2 3 2 30% 4 34.3 29 2.3 7 M NONE
115 VENI 28 64310 B 4 Booked G3A2 33.6 3 2 50% 4 35.2 10 2.5 7 M HEADACHE
116 VENI 19 62579 C 4 Booked PRIMI 36.2 3 2 30% 4 37.5 10 3 8 M NONE
117 VENNILA 19 71290 B 4 Booked PRIMI 34.1 3 2 50% 4 34.3 2 2.4 7 M HEADACHE
118 VENNILA 19 65621 B 4 Booked PRIMI 35 3 2 50% 4 37.2 16 2.5 8 M NONE
119 VICTORIYA RANI 31 60038 C 5 Booked G3P1L1A1 33.4 3 2 30% 4 34.2 5 1.9 7 A NONE
120 YOGAPRIYA 25 72352 A 4 Booked PRIMI 36.1 3 2 50% 4 36.3 4 2.6 7 M NONE
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